Could a PD-L1 test pave the way for personalized head and neck cancer treatments?

Testing for levels of PD-L1, a key immune protein, may allow doctors to personalize the treatment of head and neck cancer. New research reports that patients with varying PD-L1 levels benefited from different treatment combinations of immunotherapy and chemotherapy. Immunotherapy has improved the treatment of head and neck cancer. However, predicting which patients will respond best and personalizing treatments remains a challenge. Past analysis of the KEYNOTE-048 trial demonstrated that PD-L1 scoring systems could be used to determine who is likely to benefit from pembrolizumab immunotherapy treatment. Analysis of new data from the KEYNOTE-048 trial by researchers at The Institute...